Then, the top five higher binding energy ginsenosides were used for docking with other SLC transporters, including SLC7A5, SLC7A6, LCN2, and SLC7A9 cancer-related targets, as well as BSG due to its involvement in amino acid transport. The gene discussed is LCN2; the disease is cancer.